Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
Clinical trial NCT04431635 · TERMINATED
Trial details
- NCT number
- NCT04431635
- Sponsor
- University of Michigan Rogel Cancer Center
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-15
- Primary completion
- 2023-11-14
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.